bispecific antibodies– tag –
-
From Beginner to Expert | Bispecific Antibody Drug Series A0: What This Series Will Help You Understand
Bispecific antibody drugs have become one of the most prominent areas in cancer therapy over the past several years. Bispecific antibody drugs have become one of the most prominent areas in cancer therapy over the past several years. If ... -
Big Pharma Mega Deals in the Last Few Months Series Part 2 | Next-Generation Oncology: in vivo CAR-T, ADCs, Bispecifics and Oral Biologics
Among the many big pharma transactions announced in the last few months, oncology stands out as the area where activity is both dense and conceptually rich. Among the many big pharma transactions announced in the last few months, oncolog... -
Summer Beginner Series Grand Summary Part 2｜The Rise of Bispecific Antibodies and the Future of Next-Generation Modalities
This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. This article is the second half of the Morningglorysciences Summer Beginner Series Grand Summary. In Part 1, we reviewed anti-obesity drugs... -
Summer Beginner Series Grand Summary Part 1｜Anti-Obesity Drugs, ADCs, and In vivo CAR-T — From Beginner to Intermediate Insights
This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. This article is the first half of the Morningglorysciences Summer Beginner Series Grand Summary. We revisit three major therapeutic modaliti... -
Beginner-Friendly｜Bispecific Antibody Drug: Pharmacological Differences Based on Modalities Vol.4
Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significantly depending on the structural modality. Even among bispecific antibody drugs, the pharmacological behavior in the body can vary significa... -
Beginner-Friendly Series｜Bispecific Antibody Drug Vol.3：Strategic Considerations in Selecting Targets for Bispecific Antibody Drugs
In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we delve into the crucial question: “Which targets should be selec In this third installment of our Beginner-Friendly Bispecific Antibody Drug series, we... -
[Beginner’s Guide to Bispecific Antibody Drugs] Vol.2 – Comparing Structural Designs and Their Impact on Therapeutic Efficacy
In this second installment of our series on bispecific antibody drugs, we delve into the diverse structural formats that define the field. In this second installment of our series on bispecific antibody drugs, we delve into the diverse s... -
Oncology Drug Approval News Flash: FDA Grants Accelerated Approval to Lynozyfic (linvoseltamab) for Relapsed/Refractory Multiple Myeloma
[FDA Approval] BCMA/CD3 Bispecific Antibody Approved on July 2, 2025 On July 2, 2025, the U.S. Food and Drug Administration (FDA) granted accelerated approval to linvoseltamab (brand name: Lynozyfic) for the treatment of adults with rela... -
Biotech Investment News: AstraZeneca’s 10-Year Deal Overview & 2025 Update (2015–2025)
Strategic Review: Investing in ADCs, Rare Diseases, and Biomanufacturing Capabilities AstraZeneca has expanded significantly in oncology through antibody and ADC partnerships, including a high-profile collaboration with Japan’s Daiichi S...
1